Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in antiretroviral-naive HIV patients in Campania, Italy

Journal of Chemotherapy

Volumn 16, Issue 6, 2004, Pages 534-539

  Filippini, P ^a   Liguori, G ^a   Scolastico, C ^a   Coppola, N ^a   Lucariello, A ^a   Marrocco, C ^a   Catania, M R ^a   Ortega De Luna, L ^b   Romano Carratelli, C ^a   Marinelli, P ^a   Sagnelli, E ^a   Rossano, Fabio ^b,c  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c NONE   (Italy)

Author keywords

HAART; Highly active antiretroviral therapy; HIV infection; INNO Line Probe Assay; Zidovudine resistance

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DIDANOSINE; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; FEMALE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ITALY; MAJOR CLINICAL STUDY; MALE; NONHUMAN; RNA ANALYSIS; SIDE EFFECT; VIRUS ISOLATION; VIRUS LOAD; VIRUS MUTATION;

EID: 19944431049     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2004.16.6.534     Document Type: Article

References (54)

1. Ho D, Neuman A, Perelson A, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-126.
2. Wei X, Ghosh S, Taylor M, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995;373:117-122.
3. Frost SDW, McLean AR. Quasispecies dynamics and the emergence of drug resistance during zidovudine therapy of HIV infection. AIDS 1994;8:323-332.
4. Najera I, Holguin A, Quinones-Matei M, et al. Pol gene quasispecies of HIV: mutations associated with drug resistance in virus from patients undergoing no drug therapy. J Virol 1995;69:23-31.
5. Shafer RW. Genotyping testing for human immunodeficiency virus type 1 drug resistance. Clin Microbiol Rev 2002;15:247-277.
6. Little S, Daar E, D'Aquila R, et al. Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA 1999;282:1142-1149.
7. Boden D, Hurley A, Zhang L, et al. HIV drug resistance in newly infected individuals. JAMA 1999;282:1135-1141.
8. Brodine SK, Shaffer RA, Starkey MJ, et al. Drug resistance patterns, genetic subtypes, clinical features, and risk factors in military personnel with HIV-1 seroconversion. Ann Intern Med 1999;131:502-506.
9. Wegner S, Brodine SK, Mascola JR, et al. Prevalence of genotypic and phenotypic resistance to anti-retroviral drugs in a cohort of therapy-naïve HIV-1 infected US military personnel. AIDS 2000;14:1009-1015.
10. Pillay D, Cane PA, Shirley J, Porter K. Detection of drug resistance associated mutations in HIV primary infection within the UK. AIDS 2000;14:906-908.
11. Fitzgibbon JE, Gaur S, Frenkel LD, Laraque F, Edlin BR, Dubin DT. Transmission from one child to another of human immunodeficiency virus type 1 with a zidovudine-resistance mutation. N Engl J Med 1993;329:1835-1841.
12. Imrie A, Beveridge A, Genn W, Vizzard J, Cooper DA. Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine. Sydney Primary HIV Infection Study Group. J Infect Dis 1997;175:1502-1506.
13. Hecht FM, Grant RM, Petropoulos CJ, et al. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med 1998;339:307-311.
14. Colgrove RC, Pitt J, Chung PH, Welles SL, Japour AJ. Selective vertical transmission of HIV-1 antiretroviral resistance mutations. AIDS 1998;12:2281-2288.
15. Yerly S, Kaiser L, Race E, Bru JP, Clavel F, Perrin L. Transmission of antiretroviral-drug-resistant HIV-1 variants. Lancet 1999;354:729-733.
16. Tamalet C, Pasquier C, Yahi N, et al. Prevalence of drug resistant mutants and virological response to combination therapy in patients with primary HIV-1 infection. J Med Virol 2000;61:181-186.
17. Balotta C, Berlusconi A, Pan A, et al. Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals. Antivir Ther 2000;5:7-14.
18. Weinstock H, Respess R, Heneine W, et al. Prevalence of mutations associated with reduced antiretroviral drug susceptibility among human immunodeficiency virus type 1 seroconverters in the United States, 1993-1998. J Infect Dis 2000;182:330-333.
19. Little SJ. Transmission and prevalence of HIV resistance among treatment-naive subjects. Antivir Ther 2000;5:33-40.
20. UK Collaborative Group on Monitoring the Transmission of HIV Drug Resistance.Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom. BMJ 2001;322:1087-1088.
21. Briones C, Perez-Olmeda M, Rodriguez C, del Romero J, Hertogs K, Soriano V. Primary genotypic and phenotypic HIV-1 drug resistance in recent seroconverters in Madrid. J Acquir Immune Defic Syndr 2001;26:145-150.
22. Duwe S, Brunn M, Altmann D, et al. Frequency of genotypic and phenotypic drug-resistant HIV-1 among therapy-naive patients of the German Seroconverter Study. J Acquir Immune Defic Syndr 2001;26:266-723.
23. Goudsmit J, Weverling GJ, van der Hoek L, et al. Carrier rate of zidovudine-resistant HIV-1: the impact of failing therapy on transmission of resistant strains. AIDS 2001;15:2293-2301.
24. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002;347:385-394.
25. Grant RM, Hecht FM, Warmerdam M, et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002;288:181-188.
26. Yerly S, Vora S, Rizzardi P, et al and the Swiss HIV Cohort Study. Acute HIV infection: impact on the spread of HIV and transmission of drug resistance. AIDS 2001;15:2287-2292.
27. de Mendoza C, del Romero J, Rodriguez C, Corral A, Soriano V. Decline in the rate of genotypic resistance to antiretroviral drugs in recent HIV seroconverters in Madrid. AIDS 2002;16:1830-1832.
28. Stuyver L, Wyseur A, Rombout A, et al. Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene. Antimicrob Agents Chemother 1997;41:284-291.
29. Clarke JR, Kaye S, Babiker AG, Hooker MH, Tedder R, Weber JN. Comparison of a point mutation assay with a line probe assay for the detection of the major mutations in the HIV-1 reverse transcriptase gene associated with reduced susceptibility to nucleoside analogues. J Virol Meth 2000;88:117-124.
30. Yeni PG, Hammer SM, Carpenter CC, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA 2002;288:222-235.
31. Carpenter CC, Cooper DA, Fischl MA et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA 2000;283:381-390.
32. Rezza G, Padian N. AIDS 2000. Epidemiology: overview. AIDS 2000;14:S45-46.
33. Cesaire R, Dos Santos G, Abel S, Bera O, Sobesky G, Cabie A. Drug resistance mutations among HIV-1 strains from antiretroviral-naïve patients in Martinique, French West Indies. J Acquir Immune Defic Syndr 1999;22:401-405.
34. Sullivan PS, Buskin SE, Turner JH, et al. Low prevalence of antiretroviral resistance among persons recently infected with human immunodeficiency virus in two US cities. Int J STD AIDS 2002;13:554-558.
35. Violin M, Forbici F, Cozzi-Lepri A, et al. Primary HIV-1 resistance in recently and chronically infected individuals of the Italian Cohort Naïve for Antiretrovirals. J Biol Regul Homeost Agents 2002;16:37-43.
36. Martinez-Picado J, Savara AV, Sutton L, D'Aquila RT. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J Virol 1999;73:3744-3752.
37. Erickson JW, Gulnick SV, Markowitz M. Protease inhibitors: resistance, cross-resistance, fitness and the choice of initial and salvage therapies. AIDS 1999;13 Suppl A:S189-204.
38. Nijhuis M, Schuurman R, De Jong D, et al. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS 1999;13:2349-2359.
39. Verhofstede C, Wanzeele FV, Van der Gucht B, De Cabooter N, Plum J. Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype. AIDS 1999;13:2541-2546.
40. Devereux HL, Youle M, Johnson MA, Loveday C. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. AIDS 1999;13:F123-127.
41. Horban A, Stanczak JJ, Bakowska E, et al. High prevalence of genotypic resistance to nucleoside reverse transcriptase inhibitors among therapy-naive individuals from the Warsaw cohort. Infection 2002;30:356-359.
42. Imrie A, Carr A, Duncombe C, et al. Primary infection with zidovudine-resistant human immunodeficiency virus type 1 does not adversely affect outcome at 1 year. Sydney Primary HIV Infection Study Group. J Infect Dis 1996;174: 195-198.
43. de Ronde A, Schuurman R, Goudsmit J, van den Hoek A, Boucher C. First case of new infection with zidovudine-resistant HIV-1 among prospectively studied intravenous drug users and homosexual men in Amsterdam, the Netherlands. AIDS 1996;10:231-232.
44. Rubio A, Leal M, Pineda JA, et al. Increase in the frequency of mutation at codon 215 associated with zidovudine resistance in HIV-1 infected antiviral naive patients from 1989 to 1996. AIDS 1997;11:1184-1186.
45. Gomez-Cano M, Rubio A, Puig T, et al. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain. AIDS 1998;12:1015-1020.
46. Garcia-Lerma G, Soriano V, Gomez-Cano M, et al. Prevalence of zidovudine-resistant HIV-1 among rapid progressors. AIDS 1996;10:1292-1293.
47. D'Aquila RT, Johnson VA, Welles SL, et al. Zidovudine resistance and HIV type 1 disease progression during antiretroviral therapy. Ann Intern Med 1995;122:401-408.
48. Leriche-Guerin K, Trabaud MA, Cotte L, et al. Correlation between antiretroviral resistance mutations, biological parameters, and clinical evaluation in zidovudine-treated patients infected with HIV type 1. Eur J Clin Microbiol Infect Dis 1997;16:660-668.
49. Rubio A, Leal M, Rey C, Pineda JA, Sanchez-Quijano A, Lissen E. Short-term evolution of HIV-1 viraemia and CD4+ cell counts in patients who have a primary mutation to zidovudine. AIDS 1998;12:395-398.
50. Schmit JC, Ruiz L, Stuyver L, et al. Comparison of the LiPA HIV-1 RT test, selective PCR and direct solid phase sequencing for the detection of HIV-1 drug resistance mutation. J Virol Meth 1998;73:77-82.
51. Descamps D, Calvez V, Collin G, et al. Line probe assay for the detection of human immunodeficiency virus type 1 mutations conferring resistance to nucleoside inhibitors of reverse transcriptase: comparison with sequence analysis. J Clin Microbiol 1998;36:2143-2145.
52. Van Laethem K, Van Vaerenbergh K, Schmit JC, et al. Phenotypic assays and sequencing are less sensitive than point mutation assays for the detection of resistance in mixed HIV-1 genotypic population. J Acquir Immune Defic Syndr 1999;22:107-118.
53. Servais J, Lambert C, Fontaine E, et al. Comparison of DNA sequencing and a line probe assay for detection of human immunodeficiency virus type 1 drug resistance mutations in patients failing highly active antiretroviral therapy. J Clin Microbiol 2001;45:893-900.
54. Hirsch MS, Conway B, D'Aquila RT, et al. Antiretroviral drug resistance testing in adults with HIV infection. JAMA 1998;279:1984-1991.